Researchers have discovered that disruptions in the brain’s salience network, often tied to tau protein buildup, correlate strongly with behavioral changes in people with early-stage dementia.

The drug is RI-AG03, and it's a peptide inhibitor (a blocker of proteins). In tests on fruit flies and human cells, it has ...

A new drug targeting Tau protein shows promise in preventing its accumulation, potentially leading to more effective ...

Researchers from the University of Michigan reveal new insights into early-stage dementia, identifying tau protein as a ...

When most people think of dementia, particularly Alzheimer’s disease, they often think of memory loss first. However, ...

When most people think of dementia, including Alzheimer's disease, they probably think of memory loss first. But dementia ...

Researchers make promising breakthrough in Alzheimer’s drug development: Lancaster Monday, October 7, 2024, 11:00 Hrs [IST] An international team of researchers led by Lancaster ...

A peptide inhibitor called RI-AG03 targets major aggregation “hot spots” of tau proteins, believed to be a key driver of ...

In two papers, published in Cell and Science, they demonstrate how utilizing the unique capabilities of a protein called TRIM21 gives the potential therapies two key advantages. Firstly, they only ...

Scientists have hailed a promising breakthrough in drugs used to treat Alzheimer’s disease at the University of Southampton ...

GT-02287 Demonstrates Disease Modifying Capacity in Both GBA1 and Idiopathic Parkinson’s Disease ModelsGT-02287 Improves Mitochondrial Function ...